Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

CytoDyn names Cyrus Arman as president

By Brian Buntz | July 13, 2022

CytoDynThe biotech CytoDyn (OTCQB:CYDY) installed Cyrus Arman as president starting on July 9, 2022. Arman will assume the CEO role and join the company’s board within six months. 

Before joining CytoDyn, Arman was the chief business officer at Nimble Therapeutics (Madison, Wisconsin), assuming that role on ​​September 08, 2021. 

“Early in the process, Dr. Arman separated himself from the competition, diving deep into due diligence with a methodical, analytical and inspired approach,” said Tanya Urbach, board chair, in a statement. “He has the intellectual capacity, experience, and character to lead CytoDyn into the future.” 

Cyrys Arman

Cyrys Arman

Arman has worked in the life sciences industry for more than 15 years, which includes working as a director in Amgen’s Corporate Strategy group. 

He holds an MBA from the University of California, Los Angeles; a Ph.D. in neuroscience and a master’s degree in biomedical engineering from the University of Southern California; and a bachelor’s in biopsychology from the University of California, San Diego.

CytoDyn’s former interim President, Antonio Migliarese, will return to his prior role as CFO.

The Vancouver, Washington–based company’s lead drug candidate is the CCR5 antagonist leronlimab. 

“Leronlimab is a unique molecule with the potential to help many individuals, particularly with unmet medical needs,” said Cyrus Arman in a statement. “We will focus on enhancing shareholder value through focused execution and refining of the path forward for leronlimab.”

CytoDyn is pursuing multiple leronlimab indications, including infectious disease, cancer, and autoimmune conditions.

To date, has studied the drug candidate for COVID-19 pneumonia, graft-versus-host disease, non-alcoholic steatohepatitis and solid tumors. 

In May, CytoDyn resolved a legal dispute with Dr. Richard Pestell, the company’s former medical officer who had been “fired with cause” in 2019.


Filed Under: Drug Discovery, Drug Discovery and Development, Oncology
Tagged With: CytoDyn, leronlimab, Nimble Therapeutics
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE